Silver Book Fact

Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye Disease Study (AREDS) nutritional formula could help 300,000 of those 1.3 million avoid the severe vision loss of advanced AMD over a 5-year period.

Bressler N, Bressler S, Congdon N, Ferris F, et al. Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11. Arch Opthalmol. 2003; 121(11): 1621-4. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/415852

Reference

Title
Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11
Publication
Arch Opthalmol
Publication Date
2003
Authors
Bressler N, Bressler S, Congdon N, Ferris F, et al
Volume & Issue
Volume 121, Issue 11
Pages
1621-4
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Remote Interpretation of Retinal Imaging for DR
    Use of remote interpretation of retinal imaging in diabetics sent via tele-ophthalmology, improved the frequency of screening from 32% to 71% in only 12 months.  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • Blood Pressure Control in Patients with Diabetes
    Tight blood pressure control in type 2 diabetes patients reduced progression of DR by 34% and risk of deterioration by 47% after 9 years.  
  • Of the 8 million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years. However, the NEI-sponsored Age-Related Eye…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.